|Bid||10.29 x 800|
|Ask||12.00 x 1200|
|Day's Range||10.23 - 11.44|
|52 Week Range||6.71 - 17.63|
|Beta (5Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2020 - May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.50|
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Company’s board of directors granted the individual hired by Prothena an option to purchase 120,000 shares of the Company’s common stock. The stock option has an exercise price per share equal to $10.99, which was the closing trading price on April 1, 2020, the date of the grant. The stock option was granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting (AAT-AD/PD), to be held virtually on April 2-5, 2020. Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche. Baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease, will be presented in the following virtual oral session.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for leading Prothena’s business development initiatives, portfolio strategic planning and alliance management activities. “Brandon is a proven leader with a diverse experience across multiple sectors of the biotech industry and we are pleased to welcome him to our executive team,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena.
Prothena (PRTA) delivered earnings and revenue surprises of 16.92% and 28.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash.
NEW YORK, NY / ACCESSWIRE / February 12, 2020 / Prothena Corp. Plc (NASDAQ:PRTA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 12, 2020 at ...
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets. To access the call via dial-in, please dial (877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 1758808. A replay of the call will be available until February 26, 2020 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 1758808.
It is a pleasure to report that the Prothena Corporation plc (NASDAQ:PRTA) is up 55% in the last quarter. But only the...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in the biotechnology and scientific communities,” commented Lars Ekman, Prothena's Chairman.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Prothena (PRTA) delivered earnings and revenue surprises of 9.26% and 36.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted.
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 5. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
To: All persons and entities that purchased or acquired the publicly traded ordinary shares of Prothena Corporation plc during the period from October 15, 2015 through April 20, 2018, inclusive (the "Class Period"), and were allegedly damaged thereby (the "Settlement Class"). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of New York, that Court-appointed Lead Plaintiffs, on behalf of themselves and all members of the proposed Settlement Class, and Prothena Corporation plc ("Prothena" or the "Company"), Dr. Gene Kinney, Tran B. Nguyen, and Dr. Sarah Noonberg, M.D., Ph.D. (the "Defendants"), have reached a proposed settlement of the claims in the above-captioned class action (the "Action") in the amount of $15,750,000 (the "Settlement").
Gene Kinney became the CEO of Prothena Corporation plc (NASDAQ:PRTA) in 2016. This analysis aims first to contrast CEO...